Bipolar disorder. Bipolar affective disorder
Conditions
Interventions
Intervention 1: Intervention group:tab lithium carbonate300mg(1-1/2meq/lit) + Risperidone2-6 mg/day + memantine20 mg/day (10 mg bid). Intervention 2: Intervention group:tab lithium carbonate300mg(1-1/
Treatment - Drugs
Placebo
Intervention group:tab lithium carbonate300mg(1-1/2meq/lit) + Risperidone2-6 mg/day + memantine20 mg/day (10 mg bid)
Intervention group:tab lithium carbonate300mg(1-1/2meq/lit) + Risperidone2-6 mg/day +placebo.
Sponsors
Vice chancellor for research, Kurdistan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: This study is performed on patients between the years2013 to2014 at Qods Hospital in Sanandaj admitted with a diagnosis of bipolar1 disorder in acute mania phase. Inclusion criteria:history of bipolar disorder (manic acute phase), with or without psychotic symptoms according to DSM-IV-TR clinical interview by a psychiatrist; earn at least 20 points YMRS mania that has revealed; age 18 to 60 years old; obtaining informed consent from a parent or legal guardian of the patient; living in Sanandaj, Irann. Exclusion criteria: Alcohol and drug dependence or abuse during the 3 months prior to admission (excluding nicotine or caffeine); psychiatric disorders on Axis II (according to DSM-IV-TR), which can interfere with the study; delirium, dementia and cognitive disorders; Schizophrenia, schizoaffective disorder, and psychotic disorders; evidence of heart disease, kidney disease, liver disease (based on medical records) that may cause difficulty in the study; pregnancy and lactation; mental retardation based on clinical assessment, the therapist; history of drug allergy or adverse drug with risperidone and lithium carbonate or Memantine; any history of seizure; Memantine use of the 3 months prior to admission.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of mania. Timepoint: Baseline and weerks 1, 2, 4, 6. Method of measurement: By Young Mania Rating Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of extrapyramidal side effects. Timepoint: weerks 1, 2, 4, 6. Method of measurement: By Extrapyramidal Symptom Rating Scale(ESRS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Shahab Bahrami
Kurdistan University of Medical Sciences
Outcome results
None listed